The application relates to a
minicircle DNA expression bridging molecules for connecting human and animal target cells with
effector cells, and an application of the
minicircle DNA expression bridgingmolecules, in particular to a
minicircle DNA vector for
in vivo expression human-animal cross reaction
bispecific antibody(crBsAb). The human-animal
bispecific antibody(crBsAb) can combine human or animal target cells, and can also combine human or animal
effector cells (T cells or natural killer cells) so as to treat
cancer, infection and other diseases. Before clinical testing with medicines, the human-animal cross reaction
bispecific antibody is favorable for evaluation of the safety and the validity of bispecific
antibody drugs with an
animal model, so as to promote development process ofthe medicines. The bridging molecules are completely the same in
large animal experimentation and clinical minicircle DNA-
gene drugs for human, and the condition that in the prior art, two differenteditions of
biology drugs for common-used animal and human can cause difficult result interpretation, is avoided.